Sevoflurane attenuates endothelial glycocalyx injury during cardiopulmonary bypass surgery via sirt1 signaling pathway: a randomized controlled trial.

Sevoflurane attenuates endothelial glycocalyx injury during cardiopulmonary bypass surgery via sirt1 signaling pathway

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000034099

Enrollment

Unknown

Registered

2020-06-23

Start date

2020-06-13

Completion date

Unknown

Last updated

2020-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart disease

Interventions

Sevoflurane group:Sevoflurane

propofol group:propofol

Eligibility

Sex/Gender

All

Age

25 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients were selected for elective valve replacement or valvular shaping

Exclusion criteria

Exclusion criteria: History of cardiac surgery, dissection, pregnant woman, hemodynamic instability (requires maintenance of vasoactive drugs), severe liver disease (alanine aminotransferase or aspartate aminotransferase > 150U), renal insufficiency (creatinine>1.5mg /dl), chronic obstructive pulmonary disease (expired first second expiratory volume less than 0.8L), history of nervous system, carotid artery stenosis, severely infected patients (calcitonin>0.5ug/L, CRP greater than 8.5,), diabetes.

Design outcomes

Primary

Measure	Time frame
sirt1;	—

Secondary

Measure	Time frame
syndecan-1;HS;	—

Countries

China

Contacts

Public ContactWeijian Wang

The First Affiliated Hospital of Wenzhou Medical University

wangwj2002@163.com+86 13806683232

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026